A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Children and teens with Bipolar I Disorder (manic or mixed), schizophrenia or schizoaffective disorder

• Willingness to discontinue all antipsychotic medications during the study period

Exclusion Criteria:

• Patients who are clinically stable on treatments that are well tolerated

• Substance-induced psychotic disorders